ArticleScientific reports2021
Synthesis of [
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Recent advances in PSMA therapy - from beta to alpha.Annals of nuclear medicine · 2026Review
- Astatine-211-Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications.Medicinal research reviews · 2026Review
- Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2025Review
- Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211.International journal of molecular sciences · 2024Article
- Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target.International journal of molecular sciences · 2024Article
- Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.EJNMMI radiopharmacy and chemistry · 2024Review
- The Different Strategies for the Radiolabeling of [Pharmaceutics · 2024Review
- Preclinical Evaluation of Biodistribution and Toxicity of [International journal of molecular sciences · 2024Article
- Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.International journal of molecular sciences · 2024Article
- Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics · 2024Review
- Therapeutic efficacy ofChemical science · 2023Article
- Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology.European journal of nuclear medicine and molecular imaging · 2023Article
- Exploring a Nuclear-Selective Radioisotope Delivery System for Efficient Targeted Alpha Therapy.International journal of molecular sciences · 2023Article
- Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine.International journal of molecular sciences · 2023Article
- Targeted α-therapy using astatine (European journal of nuclear medicine and molecular imaging · 2023Article
- Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astatine-211 (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.